Los Angeles, California
SYMPOSIUM INFORMATION
>General Information
>Faculty
>Program/Schedule
>Accreditation
>Registration
>Hotel Reservations
>Privacy Policy
Supported by:
PIH Health Good Samaritan Hospital Los Angeles, CA

Officially Endorsed by:
American College of Cardiology California Chapter

|
FIFTH ANNUAL SYMPOSIUM
Contemporary Management of Cardiovascular Disease in Women
April 23, 2022
Omni Los Angeles Hotel Los Angeles California

PROGRAM / SCHEDULE
Saturday, April 23
6:45 Registration Opens
6:55-7:55 Breakfast
6:55-7:55
Product Theatre (Non-CME)
A treatment option for appropriate HFrEF patients following a
worsening HF event
• Highlight the burden of HFH in patients with HFrEF.
• Review a treatment option for reducing the risk of HFH and
CV death in appropriate patients with HFrEF.
Dr. Catherine Marti
Piedmont Heart Institute - Athens, Georgia
Supported by: Merck
Please Pre-Register for this Online Presentation by clicking on this link:
> Register
Once registered please use the link sent to your e-mail to access the program. If participants pre-register prior to the event they can avoid waiting for the link during the actual presentation.
|
8:05-8:10 Introductory Remarks
8:10-8:35 Cardiovascular Disease in Women: 2022 Update
Christina Economides, MD, MM, FSCAI
8:35-9:00 Cardiovascular Consequences of COVID: Acute and Long-term
Shira Shafir, PhD, MPH
9:00-9:25 Microvascular Disease: INOCA and MINOCA Update 2022
Janet Wei, MD, FACC
9:25-9:50 Effect of Diabetes on Cardiovascular Outcomes in Women
Karol Watson, MD, PhD
9:50-10:05 Question & Answer
10:05-10:20 Break
10:20-10:45 Current Management of Pulmonary Arterial Hypertension
Shelley Shapiro, MD, PhD, FACC
10:45-11:10 Cardio-Obstetrics: The Management of Cardiovascular Complications in Pregnancy
Priya Pillutla, MD
11:10-11:35 Update on Dyslipidemia Management in Women
Margo B Minissian, PhD, ACNP, CLS, AACC, FAHA
11:35-12:00 Effect of Intermittent Fasting and Diet on Cardiovascular Outcomes
Christina Craigo, MSN, ACNP, AACC
12:00-12:15 Question & Answer
12:30-1:30 Lunch
Product Theatre (Non-CME)
Addressing Elevated Risk For Thrombotic CV Events in Patients Across the CAD Spectrum
• Understand the risk factors that contribute to the elevated risk for thrombotic cardiovascular events pre- and post-myocardial infarction in patients across the coronary artery disease spectrum.
• Differentiate oral P2Y12 inhibitors with respect to their clinical pharmacology and examine the select differences between oral antiplatelet therapies.
• Describe the role of BRILINTA in reducing the risk of cardiovascular events in patients with acute coronary syndrome, history of myocardial infarction, and high-risk coronary artery disease without prior myocardial infarction.
Warren Fegenbush, PharmD, BCPS
Supported by: AstraZeneca Pharmaceuticals, LP
1:40-2:05 Atrial Fibrillation in Women
Anil Bhandari, MD, FACC, FHRS
2:05-2:30 Heart Failure Management in Women:
Current Landscape and Pharmacologic Management
Joseph Rahman, MD
2:30-2:55 Heart Failure Management in Women:
Current Cardiac Device Considerations
Ravi Sureddi, MD
2:55-3:20 The Era of TAVR: What is the role of SAVR?
Katrine Zhiroff, MD, FACC, FSCAI
3:20-3:35 Question & Answer
3:35-3:50 Break
3:50-4:15
Transcutaneous Mitral Valve Repair (TMVR):
Are There Gender Differences? Christina Economides, MD, MM, FSCAI
4:15-4:40 Pushing the Limits of Structural Heart Disease
Steven Burstein, MD
4:40-5:20 Major Cardiovascular Trials of 2019/2020/2021
Case-Based Presentations
Moderators:
Christina Economides, MD, MM, FSCAI
Katrine Zhiroff, MD, FACC, FSCAI
5:20-5:25 Adjourn
|